RED BANK, N.J., Oct. 1, 2020 /PRNewswire/ -- Provention Bio, Inc.
(Nasdaq:PRVB), a biopharmaceutical company dedicated to
intercepting and preventing autoimmune disease, yesterday launched
a national effort to redefine patient care in type 1 diabetes (T1D)
with two complementary disease state and screening education
campaigns. "Connected by T1D" and
"Type 1 Tested" are uniquely designed
for healthcare professionals and patients and their relatives at
increased risk of T1D, respectively, and aim to bring awareness to
the importance and urgency of screening people with a family
history of T1D for early-stage, pre-symptomatic disease.
![(PRNewsfoto/Provention Bio, Inc.) (PRNewsfoto/Provention Bio, Inc.)](https://mma.prnewswire.com/media/720849/Provention_Bio_Logo.jpg)
T1D is an autoimmune disease affecting 1.6 million Americans.
Family history puts people at a 15 times greater risk of developing
T1D. By getting screened for specific autoantibodies through a
blood test, early-stage disease can be confirmed before any signs
or symptoms appear. This action may reduce the risk of serious
complications and life-threatening events such as diabetic
ketoacidosis (DKA). It can also allow time to prepare for the onset
of clinical disease and a lifetime of insulin administration and
glucose monitoring.
Both campaigns focus on the need to screen patients at greater
risk due to having a family member(s) with T1D. Connected by
T1D also focuses on the different stages of T1D and the
beta cell destruction that occurs months and even years before
symptoms present. Type 1 Tested emphasizes that by
getting tested, parents and patients can have additional knowledge
about their health to, with their doctors, prepare for clinical
T1D, and make decisions to decrease the likelihood of DKA and
other serious complications. Early and routine autoantibody
screening is the call-to-action in each campaign.
"We are proud to launch these complementary campaigns and be
part of the T1D ecosystem empowering doctors and patients with
information," said Eleanor (Leni)
Ramos, MD, CMO, Provention Bio. "We hope this national
educational effort will inspire behavioral change by challenging
the standard clinical practice with respect to T1D, and encourage
autoantibody screening for relatives of people living with the
disease. Both are essential to redefining what patient care looks
like for this chronic, life-altering, and life-threatening
disease."
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical
company focused on advancing the development of investigational
therapies that may intercept and prevent debilitating and
life-threatening immune-mediated disease. The company's lead
investigational drug candidate, teplizumab, is currently under
review by FDA for the delay or prevention of insulin-dependent type
1 diabetes (T1D) in at-risk patients during the pre-symptomatic
phase of the disease. The Company's pipeline includes additional
clinical product development candidates that have
demonstrated in pre-clinical or clinical studies
proof-of-mechanism and/or proof-of-concept in other autoimmune
diseases, including celiac disease and lupus. Visit
ProventionBio.com for more information or follow us on
Twitter: @Proventiobio
Investor Contact:
Sam
Martin, Argot Partners
sam@argotpartners.com
212-600-1902
Media:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-announces-national-effort-to-redefine-patient-care-in-type-1-diabetes-t1d-301143721.html
SOURCE Provention Bio, Inc.